Concert Pharmaceuticals Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Concert Pharmaceuticals (CNCE) PT Lowered to $18 at UBS
May 6, 2016 9:02 AM EDTUBS analyst Jeffrey Hung lowered his price target on Concert Pharmaceuticals (NASDAQ: CNCE) to $18.00 (from $28.00) but maintained a Buy rating following Q1 results.
Hung commented, "This morning, Concert reported 1Q16 results, but not surprisingly the focus of the call was on the... More
Concert Pharma (CNCE) Misses Q1 EPS by 18c
May 5, 2016 7:07 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.63), $0.18 worse than the analyst estimate of ($0.45).
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More